Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cognition Therapeutics (CGTX) Depreciation & Amortization (CF) (2020 - 2025)

Cognition Therapeutics (CGTX) reported Depreciation & Amortization (CF) of $14000.0 for Q4 2025, down 48.15% year-over-year from $27000.0 in Q4 2024, and down 6.67% on a QoQ basis from $15000.0 in Q3 2025.

Cognition Therapeutics (CGTX) has 6 years of Depreciation & Amortization (CF) data on file, last reported at $14000.0 in Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 48.15% year-over-year to $14000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $29000.0 (down 63.75% YoY) and the FY2025 annual result came in at $36000.0, down 66.36% from the prior year.
  • Depreciation & Amortization (CF) retreated to $14000.0 in Q4 2025 per CGTX's latest filing, from $15000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $27000.0 in Q4 2023 and bottomed at $14000.0 in Q4 2025.
  • The 5-year median for Depreciation & Amortization (CF) is $23000.0 (2021), against an average of $22666.7.
  • The widest annual swing landed in 2024, when Depreciation & Amortization (CF) gained 28.57%; it then slumped 48.15% in 2025.
  • Tracing CGTX's Depreciation & Amortization (CF) over 5 years: stood at $23000.0 in 2021, then changed by 0.0% to $23000.0 in 2022, then grew by 17.39% to $27000.0 in 2023, then changed by 0.0% to $27000.0 in 2024, then tumbled by 48.15% to $14000.0 in 2025.
  • Per Business Quant, the three latest CGTX Depreciation & Amortization (CF) figures stand at $14000.0 (Q4 2025), $15000.0 (Q3 2025), and $27000.0 (Q4 2024).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation & Amortization (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn - -
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn - 1,395.22
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn -
4 Nanobiotix 2,282.79 Bn 2,282.72 Bn - -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn - -
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn 55.90 Mn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn 123.20 Mn
8 Evaxion A 65.44 Bn 65.42 Bn - -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn 13.55 Mn
10 Cognition Therapeutics 648,270.00 648,270.00 - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 14,000.00
Dec 31, 2025 14,000.00
Sep 30, 2025 15,000.00
Sep 30, 2025 15,000.00
Dec 31, 2024 27,000.00
Dec 31, 2024 27,000.00
Sep 30, 2024 27,000.00
Sep 30, 2024 27,000.00
Jun 30, 2024 26,000.00
Jun 30, 2024 26,000.00
Mar 31, 2024 27,000.00
Mar 31, 2024 27,000.00
Dec 31, 2023 27,000.00
Dec 31, 2023 27,000.00
Sep 30, 2023 25,000.00
Sep 30, 2023 25,000.00
Jun 30, 2023 23,000.00
Jun 30, 2023 23,000.00
Mar 31, 2023 21,000.00
Mar 31, 2023 21,000.00
Dec 31, 2022 23,000.00
Dec 31, 2022 23,000.00
Sep 30, 2022 22,000.00
Sep 30, 2022 22,000.00
Jun 30, 2022 20,000.00
Jun 30, 2022 20,000.00
Mar 31, 2022 18,000.00
Mar 31, 2022 18,000.00
Dec 31, 2021 23,000.00
Dec 31, 2021 23,000.00
Sep 30, 2021 23,000.00
Sep 30, 2021 23,000.00
Jun 30, 2021 24,000.00
Jun 30, 2021 24,000.00
Mar 31, 2021 23,000.00
Mar 31, 2021 23,000.00
Dec 31, 2020 24,000.00
Dec 31, 2020 24,000.00